Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene Ltd (HK:6160)
HKEX:6160
Holding HK:6160?
Track your performance easily
6160 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$75.45 - HK$127.70
Previous CloseHK$119.2
Volume1.89M
Average Volume (3M)1.34M
Market Cap
HK$169.92B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 07, 2024EPS Estimate
-HK$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding1,353,730,830
10 Day Avg. Volume1,725,423
30 Day Avg. Volume1,340,118
Standard Deviation0.14
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.01
Price to Sales (P/S)6.26
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$153.39Price Target Upside28.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BeiGene Ltd News
PremiumCompany Announcements
BeiGene Announces EGM Record Date for Domicile Shift
PremiumCompany Announcements
BeiGene Ltd. Employees Buy Shares Under Company Plan
PremiumCompany Announcements
BeiGene Launches Employee Stock Purchase Offering
PremiumCompany Announcements
BeiGene Announces New Share Option Grants
PremiumCompany Announcements
BeiGene Reports Strong Revenue Growth and Reduced LossesOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.80% Mutual Funds
4.15% Other Institutional Investors
93.05% Public Companies and
Individual Investors
6160 FAQ
What was BeiGene Ltd’s price range in the past 12 months?
BeiGene Ltd lowest stock price was HK$75.45 and its highest was HK$127.70 in the past 12 months.
What is BeiGene Ltd’s market cap?
Currently, no data Available
When is BeiGene Ltd’s upcoming earnings report date?
BeiGene Ltd’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were BeiGene Ltd’s earnings last quarter?
BeiGene Ltd released its earnings results on Aug 27, 2024. The company reported -HK$0.69 earnings per share for the quarter, beating the consensus estimate of -HK$1.315 by HK$0.625.
Is BeiGene Ltd overvalued?
According to Wall Street analysts BeiGene Ltd’s price is currently Undervalued.
Does BeiGene Ltd pay dividends?
BeiGene Ltd does not currently pay dividends.
What is BeiGene Ltd’s EPS estimate?
BeiGene Ltd’s EPS estimate is -HK$0.94.
How many shares outstanding does BeiGene Ltd have?
BeiGene Ltd has 1,263,937,700 shares outstanding.
What happened to BeiGene Ltd’s price movement after its last earnings report?
BeiGene Ltd reported an EPS of -HK$0.69 in its last earnings report, beating expectations of -HK$1.315. Following the earnings report the stock price went up 0.744%.
Which hedge fund is a major shareholder of BeiGene Ltd?
Currently, no hedge funds are holding shares in HK:6160
---
BeiGene Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$153.39 (28.68% Upside)
HK$153.39 (28.68% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.14%
12-Months-Change
Fundamentals
Return on Equity
-14.60%
Trailing 12-Months
Asset Growth
-0.66%
Trailing 12-Months
Company Description
BeiGene Ltd
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
---
6160 Stock 12 Month Forecast
Average Price Target
HK$153.39
▲(28.68% Upside)
Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
China Yuhua Education Corp. Ltd.
―
China Tianrui Automotive Interiors Co., Ltd.
―
Best Analysts Covering 6160
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
-4.35%
reiterated a buy rating 2 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -4.35% per trade.
---